Literature DB >> 15073489

Progression of renal disease: new insights into risk factors and pathomechanisms.

Marie-Luise Gross1, Kerstin Amann.   

Abstract

PURPOSE OF REVIEW: Progression of renal failure, irrespective of the primary cause, is characterized by modification of renal structure, which culminates in terminal renal insufficiency. Interfering with progression continues to be a major challenge and is at the forefront of renal research. This review focuses on recent progress in the understanding of the mechanisms of progression and efforts to interfere with this process. RECENT
FINDINGS: In addition to the long-known risk factors (hypertension and inadequate activation of the renin-angiotensin system), several novel risk factors and pathomechanisms, such as obesity, hyperglycemia, smoking, and several hormones, have recently been identified and investigated. Furthermore, the specific and blood pressure-independent pathogenetic roles of the sympathetic nervous system and the endothelin system in progression have been further clarified. Finally, novel animal models and techniques for studying specific aspects of progression have been developed and introduced.
SUMMARY: Recently, considerable progress has been made concerning novel risk factors, understanding the underlying pathomechanisms, and interfering with the course of progression of renal diseases. Such improved insights will undoubtedly lead to new strategies in the future.

Entities:  

Mesh:

Year:  2004        PMID: 15073489     DOI: 10.1097/00041552-200405000-00007

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  2 in total

1.  Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Authors:  Jaroslav A Hubacek; Silvie Bloudickova; Ruzena Kubinova; Hynek Pikhart; Ondrej Viklicky; Martin Bobak
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

2.  A low-carbohydrate diet may prevent end-stage renal failure in type 2 diabetes. A case report.

Authors:  Jørgen Vesti Nielsen; Per Westerlund; Per Bygren
Journal:  Nutr Metab (Lond)       Date:  2006-06-14       Impact factor: 4.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.